Peptides Similar to Liraglutide
Compare Liraglutide with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Semaglutide: Very High - Same target (GLP-1R), same developer (Novo Nordisk), same design principle (acylated GLP-1 analog), but semaglutide is the next-generation molecule with superior efficacy and weekly dosing
- •Tirzepatide: High - Both are injectable incretin-based therapies for T2D and weight management with dose escalation
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Liraglutide (current) | - | - |
| Semaglutide | Very High - Same target (GLP-1R), same developer (Novo Nordisk), same design principle (acylated GLP-1 analog), but semaglutide is the next-generation molecule with superior efficacy and weekly dosing | Semaglutide uses a C18 fatty diacid with mini-PEG linker and Aib2 substitution for a 7-day half-life (weekly dosing), while liraglutide uses a C16 fatty acid for a 13-hour half-life (daily dosing). |
| Tirzepatide | High - Both are injectable incretin-based therapies for T2D and weight management with dose escalation | Tirzepatide is a dual GIP/GLP-1 receptor agonist with a C20 fatty diacid, while liraglutide is a selective GLP-1 agonist with a C16 fatty acid. Tirzepatide is weekly; liraglutide is daily. |
| Exenatide | High - Both are injectable GLP-1 receptor agonists approved for T2D | Exenatide is a 39-amino-acid synthetic exendin-4 from Gila monster venom (53% GLP-1 homology), while liraglutide is a 31-amino-acid human GLP-1 analog (97% homology). Different molecular origins. |
SemaglutideVery High - Same target (GLP-1R), same developer (Novo Nordisk), same design principle (acylated GLP-1 analog), but semaglutide is the next-generation molecule with superior efficacy and weekly dosing
Differences
Semaglutide uses a C18 fatty diacid with mini-PEG linker and Aib2 substitution for a 7-day half-life (weekly dosing), while liraglutide uses a C16 fatty acid for a 13-hour half-life (daily dosing).
Advantages
Greater weight loss (14.9% vs 8.0%), superior HbA1c reduction, weekly dosing convenience, oral formulation available (Rybelsus), proven CV benefit in non-diabetic obesity (SELECT)
Disadvantages
Higher cost (though narrowing), more potent GI side effects at equivalent efficacy levels, no pediatric obesity approval yet in all markets
TirzepatideHigh - Both are injectable incretin-based therapies for T2D and weight management with dose escalation
Differences
Tirzepatide is a dual GIP/GLP-1 receptor agonist with a C20 fatty diacid, while liraglutide is a selective GLP-1 agonist with a C16 fatty acid. Tirzepatide is weekly; liraglutide is daily.
Advantages
Greater weight loss (20.9-22.5% vs 8.0%), superior HbA1c reduction, weekly dosing, dual receptor mechanism
Disadvantages
Higher cost, shorter market track record, no proven cardiovascular outcomes benefit yet (SURPASS-CVOT pending)
ExenatideHigh - Both are injectable GLP-1 receptor agonists approved for T2D
Differences
Exenatide is a 39-amino-acid synthetic exendin-4 from Gila monster venom (53% GLP-1 homology), while liraglutide is a 31-amino-acid human GLP-1 analog (97% homology). Different molecular origins.
Advantages
First GLP-1 RA ever approved (historic), once-weekly formulation (Bydureon) available, distinct molecular origin
Disadvantages
Lower efficacy for HbA1c and weight loss, no proven CV benefit (EXSCEL neutral), higher immunogenicity risk, injection site nodules with microsphere formulation
Peptides Related to Liraglutide#
Liraglutide belongs to the GLP-1 receptor agonist therapeutic class. As one of the earliest long-acting GLP-1 analogs, liraglutide established many clinical paradigms for the class but has been largely superseded by newer agents with greater efficacy. Understanding how liraglutide compares to alternatives is essential for clinical decision-making and understanding the evolution of incretin-based therapies.
Semaglutide (Ozempic / Wegovy / Rybelsus)#
Semaglutide is liraglutide's direct successor from Novo Nordisk, representing a next-generation molecular optimization of the same acylated GLP-1 analog design principle.
Mechanism comparison: Both are selective GLP-1 receptor agonists based on the human GLP-1(7-37) backbone. Semaglutide adds two key improvements: an Aib substitution at position 2 for DPP-4 resistance, and a C18 fatty diacid with mini-PEG linker (versus liraglutide's C16 fatty acid with glutamic acid spacer).
Clinical efficacy: Semaglutide demonstrates substantially greater efficacy:
- Weight loss: 14.9% (STEP 1) versus 8.0% (SCALE Obesity)
- HbA1c reduction: 1.5-2.2% versus 1.0-1.5%
- PIONEER 4 directly compared oral semaglutide 14 mg to liraglutide 1.8 mg in T2D, showing semaglutide was non-inferior for HbA1c and superior for weight loss
Cardiovascular outcomes: Both have positive CV outcomes trials, though semaglutide's data are stronger:
- LEADER (liraglutide): 13% MACE reduction in T2D patients
- SELECT (semaglutide): 20% MACE reduction in non-diabetic obesity with CVD
Practical advantages of liraglutide: Despite lower efficacy, liraglutide has advantages including adolescent obesity approval (since 2020), generic availability (since 2025), and the longest market track record of any modern GLP-1 agonist.
| Parameter | Liraglutide | Semaglutide |
|---|---|---|
| Dosing frequency | Daily | Weekly (SC) or daily (oral) |
| Max dose (obesity) | 3.0 mg | 2.4 mg |
| Weight loss (obesity) | 8.0% | 14.9-16.0% |
| HbA1c reduction (T2D) | 1.0-1.5% | 1.5-2.2% |
| Half-life | ~13 hours | ~7 days |
| CV outcomes | Positive (LEADER) | Positive (SUSTAIN-6, SELECT) |
| Generic available | Yes (2025) | Not yet |
| Pediatric approval | Yes (12+) | Pending in most markets |
Tirzepatide (Mounjaro / Zepbound)#
Tirzepatide represents a different approach: dual GIP/GLP-1 receptor agonism rather than selective GLP-1 activation.
Efficacy comparison: Tirzepatide produces the greatest weight loss and HbA1c reduction of any approved incretin therapy. In SURMOUNT-1, tirzepatide 15 mg achieved 20.9% weight loss versus liraglutide's 8.0% in SCALE Obesity.
Key trade-off: Tirzepatide offers superior efficacy but lacks proven CV outcomes (pending SURPASS-CVOT) and has a shorter safety track record (approved 2022 vs 2010).
Exenatide (Byetta / Bydureon)#
Exenatide is historically significant as the first GLP-1 RA ever approved (2005) but is molecularly distinct from liraglutide.
Molecular differences: Exenatide is based on exendin-4 from Gila monster venom (53% homology to human GLP-1), while liraglutide is a human GLP-1 analog (97% homology). This difference contributes to higher immunogenicity with exenatide.
LEAD-6 comparison: Liraglutide 1.8 mg demonstrated superior HbA1c reduction versus exenatide 10 mcg BID (-1.1% vs -0.8%) with comparable weight loss.
Summary Comparison#
| Feature | Liraglutide | Semaglutide | Tirzepatide | Exenatide |
|---|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 | GIP + GLP-1 | GLP-1 |
| Dosing | Daily SC | Weekly SC / daily oral | Weekly SC | BID SC / weekly SC |
| Weight loss | 8.0% | 14.9-16% | 20.9-22.5% | 2-3% |
| CV outcomes | Positive | Positive | Pending | Neutral |
| Regulatory | Approved (2 brands) | Approved (3 brands) | Approved (2 brands) | Approved (2 brands) |
| Market since | 2010 | 2017 | 2022 | 2005 |
| Generic | Yes (2025) | Not yet | Not yet | Not yet |
Related Reading#
Frequently Asked Questions About Liraglutide
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer